肝素涂层Viabahn覆膜支架治疗股腘动脉病变的个体患者数据荟萃分析
本研究为个体患者数据荟萃分析,纳入977例患者(1023条患肢),评估肝素涂层Viabahn覆膜支架治疗股腘动脉病变的效果。1年一期、一期辅助和二期通畅率分别为80.6%、89.1%和95.7%,5年分别为54.8%、68.9%和85.3%。年轻、女性和闭塞性病变是一期通畅率丢失的独立预测因素。
要点
- 肝素涂层Viabahn支架2年内安全性和通畅率可接受,5年结论需更长随访。
- 年轻、女性和闭塞性病变是1年一期通畅率丢失的独立预测因素。
- 小尺寸支架(5-6 mm)1年一期通畅率低于大尺寸(7-8 mm),但非独立预测因素。
核心结论
- 肝素涂层Viabahn覆膜支架具有良好的安全性,2年内通畅率可接受,但需更长随访数据以得出5年稳健结论。
- 年轻年龄、女性和闭塞性病变是通畅率丢失的独立预测因素,强调根据个体特征制定随访策略的重要性。
研究设计与样本
- 本研究为个体患者数据(IPD)荟萃分析,遵循PRISMA 2020 IPD指南,纳入所有报告肝素涂层Viabahn覆膜支架治疗股腘动脉病变结局的数据库病例。
- 共纳入977例患者(1023条治疗肢体),收集基线特征、病变特征、手术和住院细节以及所有随访数据。
主要发现
- 1年一期、一期辅助和二期通畅率分别为80.6%、89.1%和95.7%;5年分别为54.8%、68.9%和85.3%。
- 免于靶病变血运重建率在1年、2年和5年随访时分别为85.3%、77.2%和63.0%。
- 大截肢发生在15/1023条肢体(1.5%),其中12例基线表现为慢性肢体威胁性缺血。
- 免于主要不良肢体事件率在1年、2年和5年随访时分别为82.4%、72.5%和56.6%。
- 随访期间踝肱指数和Rutherford分级改善,持续临床获益。
关键数值与推荐
- 年轻年龄(HR 0.947,P < .001)和女性(HR 1.752,P = .002)是1年一期通畅率丢失的预测因素。
- 闭塞性病变相比狭窄性病变更常导致1年一期通畅率(HR 1.615,P = .017)、一期辅助通畅率(HR 2.141,P = .013)和二期通畅率(HR 2.240,P = .028)失败。
- 小尺寸支架(5-6 mm)相比大尺寸支架(7-8 mm)1年一期通畅率显著更低(78.8% vs 90.0%,P < .001),但非独立预测因素(HR 1.921,P = .096)。
- 基于Rutherford分级、流出血管数量、病变长度、TASC II分类和钙化程度的亚组间一期通畅率丢失无差异。
临床怎么用
- 肝素涂层Viabahn覆膜支架可用于股腘动脉病变,2年内安全性和通畅率可接受。
- 对年轻、女性和闭塞性病变患者应加强随访,个体化制定监测策略。
- 小尺寸支架(5-6 mm)通畅率较低,选择支架尺寸时需综合考虑。
局限性
- 5年随访数据有限,需更长随访以得出稳健结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aims to analyze available data on patients the latest-generation heparin-bonded Viabahn endoprosthesis in the femoropopliteal artery. DESIGN: This study is an individual patient data (IPD) meta-analysis. METHODS: This study incorporated all available cases from databases that reported outcomes of patients treated with the heparin-bonded Viabahn endoprosthesis in the femoropopliteal artery. The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 IPD Guidelines were followed. All eligible centers were invited to contribute. Authors were asked to provide anonymized patient information: patient characteristics at baseline, lesion, procedural, and hospitalization details, and data of all follow-up visits. RESULTS: A total of 977 patients were included (1023 treated limbs). One-year primary, primary-assisted, and secondary patency rates were 80.6%, 89.1%, and 95.7%, respectively, and 5-year rates were 54.8%, 68.9%, and 85.3%, respectively. Freedom from target lesion revascularization was 85.3%, 77.2%, and 63.0% at 1-, 2-, and 5-year follow-up, respectively. Major amputations were performed in 15/1023 limbs (1.5%); 12 presented with chronic limb-threatening ischemia at baseline. Freedom from major adverse limb events was 82.4%, 72.5%, and 56.6% through 1-, 2-, and 5-year follow-up, respectively. Sustained clinical benefit was observed by improved ankle-brachial index and Rutherford classification throughout follow-up. Younger age (hazard ratio [HR] 0.947, P < .001) and female sex (HR 1.752, P = .002) were predictors for loss of 1-year primary patency. Occlusive lesions failed more often in 1-year primary (HR 1.615, P = .017), primary-assisted (HR 2.141, P = .013), and secondary patency (HR 2.240, P = .028) compared with stenotic lesions. One-year primary patency was significantly lower in smaller (5-6 mm) compared with larger endoprosthesis (7-8 mm); 78.8% versus 90.0% (P < .001), although not an independent predictor of failing patency (HR 1.921, P = .096). No differences were observed in loss of primary patency in subgroups based on Rutherford classification, the number of run-off vessels, lesion length, Trans-Atlantic Inter-Society Consensus II (TASC II) II classification, and degree of calcification. CONCLUSION: The heparin-bonded Viabahn endoprosthesis demonstrates a good safety profile and acceptable patency rates through 2 years. Longer follow-up data is needed to draw robust conclusions through 5 years. Independent predictors of patency loss include younger age, female sex, and occlusive lesions, highlighting the importance of tailoring follow-up strategies to individual patient and lesion characteristics.Clinical ImpactWhat does this study/review add to the existing literature and how will it influence future clinical practice?This Individual-Patient-Data meta-analysis includes 977 patients with 1023 treated limbs, representing, to our knowledge, the largest cohort reported in the literature. It provides a comprehensive assessment of the performance of the latest generation Viabahn endoprosthesis in the treatment of complex femoropopliteal lesions. By identifying key predictors of patency and analyzing relevant subgroups, this study offers valuable insights into which patients benefit most from this treatment.
引用
- Wetzels H, Holewijn S, Zomer S, et al. Individual Patient Data Meta-Analysis of GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface for Treatment of Femoro-Popliteal Arterial Disease (INSIGHT VSX). J Endovasc Ther. 2026. PMID: 42635116. doi:10.1177/15266028261479523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。